ROIV

Roivant Sciences Ltd.

Pharmaceutical Preparations · SIC 2834CIK 1635088Held by 7 tracked managersEDGAR filings ↗10-K/10-Q ↗

SHARE:X LINKEDIN EMAIL

7 managers · Q2 2026 13F

13F bookWeight

Greenlight Capital (DME)

David EinhornPosition history →

1.9%

—

$76.2M

$3.91B13F book · 2026-06-30

Maverick Capital

Lee AinsliePosition history →

0.90%

+73.9%

$100.1M

$11.08B13F book · 2026-06-30

Baker Bros. Advisors

Baker Bros. AdvisorsPosition history →

0.84%

(3.1%)

$166.9M

$19.96B13F book · 2026-06-30

Platinum Investment Management

Platinum Investment ManagementPosition history →

0.80%

—

$3.3M

$0.41B13F book · 2026-06-30

Viking Global Investors

Andreas HalvorsenPosition history →

0.63%

(5.7%)

$221.9M

$35.08B13F book · 2026-06-30

Adage Capital Management

Adage Capital ManagementPosition history →

0.51%

(19.1%)

$366.3M

$71.32B13F book · 2026-06-30

Polen Capital Management

PolenPosition history →

<0.01%

NEW

$0.3M

$11.61B13F book · 2026-06-30

Weight = position value ÷ the manager's total 13F long-equity value in the same filing — one definition for every row. “1st obs.” marks a position with no earlier stored 13F to compare against — it is not shown as a purchase.